Evidence map›Paper›PMID 21079905›Full record

ReviewDer Internist2010

[Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].

J Rademacher, M W Pletz, T Welte

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Bronchiectasis--diagnosis and treatment.Deutsches Arzteblatt international · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

J RademacherAbteilung Pneumologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, Hannover, Germany. Rademacher.jessica@mh-hannover.de
M W Pletz
T Welte
Medizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bronchiectasis has become more rarely because of the development of antibiotic therapy and vaccination. At present the great majority of bronchiectasis is more likely caused by congenital disorders than by infective reasons. Therapeutic strategies based on the experiences from cystic fibrosis and chronic obstructive pulmonary disease are not always conferrable to patients suffering from bronchiectasis. There are not enough controlled studies to give evidence-based recommendations in the treatment of bronchiectasis, which are not associated with cystic fibrosis. Goals in the treatment are improvement of the mucociliar clearance, the therapy of infections and treatment of inflammation. Currently several agents are under examination. To improve the prognosis and therapy options it would be reasonable to build up a national register for patients with bronchiectasis.

Indexed as

Administration, InhalationAnti-Bacterial AgentsAnti-Inflammatory AgentsBronchiectasisCystic FibrosisDrug Resistance, BacterialDrug Therapy, CombinationEvidence-Based MedicineExpectorantsHemoptysisHumansMucociliary ClearancePrognosisAnti-Bacterial AgentsAnti-Inflammatory AgentsExpectorants

Identifiers

PMID21079905
OpenAlexW1587646157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.